Source link : https://www.newshealth.biz/health-news/alzheimers-trials-fail-blood-test-predicts-tau-neuroscience-moves-to-bluesky/
Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer’s disease patients in the ReThink-ALZ phase III trial, Cassava Sciences reported. The company stopped a second phase III study of the controversial drug. The INVOKE-2 phase II trial of investigational AL002 also did not slow clinical progression in people with early Alzheimer’s disease, according […]
Author : News Health
Publish date : 2024-11-26 19:05:51
Copyright for syndicated content belongs to the linked Source.